BBK Worldwide makes clinical engagement process easier with mobile apps

BBK Worldwide, a leading clinical trial marketing firm, has unveiled two new mobile apps for patient and site engagement, My Clinical Study Buddy℠ and My Clinical Study Buddy℠ Protocol Pointers Edition. Available for Apple® and Android™ mobile phones and tablets, both apps are available on the App Store℠ and Google Play™ and are being demoed at this week's DIA 2014 50th Annual Meeting at the San Diego Convention Center, San Diego, Calif., June 16-19 at BBK booth #2309.

BBK's My Clinical Study BuddySM helps pharmaceutical companies optimize the millions of dollars spent on patient recruitment advertising annually by keeping patients engaged and more actively involved throughout the study. My Clinical Study BuddySM provides enrolled patients with everything they need relating to their specific study, including appointment reminders and visit details, resources and videos, and maps and site contact links, readily available and at their finger-tips. By leveraging the company's comprehensive recruitment platform TrialCentralNetSM (TCN®) - a system that streamlines, organizes, and provides on-demand analysis of all data, processes and activities - the app is highly customizable and easily updatable in real-time based on user patterns and needs and/or protocol changes. Additionally, new apps can be built on the TCN® platform in weeks or a few months, versus several months to a year, saving sponsors valuable time, budget and resources.

Consumers continue to drive the demand for information anywhere and anytime - and patients involved in clinical trials, as well as the sponsors managing those trials are no exception. Smartphones accounted for more than half of all mobile phone sales in 2013, with more than half of those owners using their devices to get health info and one-fifth of owners having at least one health app on their phone, according to Pew Research data. By 2017, it is estimated that half of the 3.4 billion smartphone or tablet users worldwide will be using mobile health apps. Not surprisingly, mobile-friendly patient recruitment campaigns are greatly enhancing enrollment and retention.

  • My Clinical Study Buddy℠: Designed to help study participants stay informed and navigate the study every step of the way, the app offers several key features: "Visit Planner" which includes visit descriptions so patients know what to expect for each visit, a calendar managing reminders and visits, and links to office locations and maps; "Study Resources" which includes educational resources, articles and related videos; and "Study Contacts."
  • My Clinical Study Buddy℠ Protocol Pointers Edition: Designed to help sites and patient recruitment specialists enhance recruitment efforts, the app offers related tutorials, protocol information and real-time updates.

"Providing patients and sites with the information they need, when they need it, is a key competitive differentiator in today's increasing competitive clinical landscape – and a strategic imperative when it comes to patient advocacy and engagement," said Aaron Fleishman, leader of BBK's social innovation group. "Mobile will continue to help the life sciences industry reduce overall trial costs and is no longer simply a nice-to-have. The companies pulling ahead have made it a core element of their patient engagement strategy."

"Our clients require an adaptive model - one that utilizes technology-based solutions and can change in near real-time as the sponsor's needs change, and as adjustments are required - and mobile remains a key driver in this shift," said Matthew Stumm, BBK principal, creative and media strategy. "Mobile will continue to revolutionize every step of the clinical trial process, and we will continue to innovate in this space to deliver our clients and their patients the tools they need to succeed, today and in the future."

"As the industry continues to leverage technology and reap the rewards inherent in a digital ecosystem, mobile solutions will help pharma drive efficiencies and stay competitive, while remaining focused on the end-goal; delivering better, safer therapies to market as quickly and cost-effectively as possible," continued Stumm.

About BBK Worldwide
With more than three decades of experience across a wide variety of therapies and medicines, BBK Worldwide is the global leader in patient recruitment for the clinical trial industry. BBK's latest innovation is the introduction of adaptive recruitment - a new specialty in clinical trial marketing proven to protect global enrollment integrity, specifically within a changing or threatened landscape. BBK is a privately held, women owned business, headquartered in Needham, Mass.

Most Popular Now

Pfizer begins a Phase 1/2 study to evaluate respir…

Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV i...

Eczema drug effective against severe asthma

Two new studies of patients with difficult-to-control asthma show that the eczema drug dupilumab alleviates asthma symptoms and improves patients' ability to breathe bett...

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

Novartis data at ASCO and EHA reinforce company's …

Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 1-5 ...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

Study demonstrates new treatment for severe asthma

Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton, together with colleagues at other partnering ...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...